June 2026 Research Update

Together, these studies show that diagnosing familial Mediterranean fever (FMF) can require more than one type of information: symptoms over time, blood or stool inflammation markers, and sometimes stepwise genetic testing. The overall direction was that broader follow-up testing can pick up a few additional genetic causes, and that certain symptom patterns (especially belly pain) can be hard to tell apart from other conditions in the moment. [1] [2] [3] [4]

In a retrospective study of 478 Turkish children evaluated for possible FMF, initial screening for common MEFV gene variants by real-time PCR found at least one MEFV variant in 211 children. In the smaller subset who then had targeted next-generation sequencing (NGS), NGS confirmed PCR-positive results and reclassified 8 of 21 previously PCR-negative cases as variant-positive (4 with MEFV variants and 4 with variants in other genes), raising overall MEFV detection to 215 of 478. [1]

That same NGS follow-up also found additional variants beyond what PCR reported, including variants in other autoinflammatory-related genes (such as NLRP12, ELANE, and TNFRSF1A) in a few children, and in additional non-MEFV autoinflammatory-associated genes (including NOD2, STAT3, and MVK). In plain language, this suggests that when initial genetic screening does not explain symptoms, a broader panel may uncover other inherited conditions that can look similar to FMF. [1]

A separate retrospective study of 81 children with FMF who had gastrointestinal symptoms compared stool inflammation levels (fecal calprotectin) with colonoscopy results. Fecal calprotectin was higher in children who were found to have inflammatory bowel disease than in those with normal or nonspecific colonoscopy findings, and a level below 123 ug/g predicted a normal colonoscopy with high sensitivity and specificity. [4]

Two pediatric case reports highlighted how FMF belly attacks can be mistaken for acute appendicitis, including one child who underwent appendectomy before FMF was recognized. In another single-patient report, a 4-year-old girl had persistent fever as her main symptom and improved after colchicine was started when genetic testing was not available; this illustrates that fever without a clear cause can still fit FMF in some children, though this was only one case. [2] [3]

For patients and caregivers, this set of papers mainly adds background about why FMF can be hard to sort out from look-alike illnesses, especially in children with abdominal pain, ongoing fever, or bowel symptoms. The strongest evidence here comes from two moderate-sized retrospective studies suggesting that (1) broader genetic testing may explain a small additional number of suspected FMF cases after initial screening and may point toward other inherited inflammatory conditions, and (2) a stool inflammation test may help separate children more likely to have inflammatory bowel disease from those with normal colonoscopy results. What remains uncertain is how well these results apply in other countries and health systems, and how often these extra genetic findings change a final diagnosis or long-term outcomes. [1] [4]

Across these studies, colchicine use in familial Mediterranean fever (FMF) looked closely tied to day-to-day disease control and to long-term complication awareness, but knowledge gaps were common. A separate long-term pediatric dataset showed that some children were able to remain attack-free after colchicine was stopped, yet this was uncommon and hard to predict ahead of time. Overall, the research suggests both adherence and informed understanding matter, while the reasons some patients can remain well without colchicine remain uncertain. [5] [6]

In a single-center cross-sectional study of 185 FMF patients in an endemic region, 78% reported regular colchicine use, and regular use was linked to fewer attacks in the multivariable analysis. Only 27% said they were aware of amyloidosis, even though 83% were aware that FMF can lead to kidney failure. Amyloidosis awareness was related to factors like education and age, suggesting that understanding of this specific complication may lag behind general awareness of kidney risk. [5]

In a retrospective pediatric cohort of 2316 children with FMF, 127 stopped colchicine and 96 maintained sustained colchicine-free remission over a median follow-up of about 5 years. No amyloidosis was observed in the group that discontinued colchicine during follow-up, but only about 4% of the full cohort achieved sustained colchicine-free remission. Children who continued colchicine tended to have more severe clinical features and a higher frequency of certain genetic variants, yet the study did not identify a strong baseline predictor that reliably separated those who could stop from those who could not. [6]

For patients and caregivers, this month highlights two practical issues: (1) taking colchicine regularly and understanding why it is used are not the same thing, and awareness of amyloidosis may be particularly low in some settings; and (2) some children in long-term follow-up remained well after colchicine was stopped, but this was uncommon and could not be reliably predicted from baseline characteristics in that study. These results are most useful as background for informed conversations and shared understanding of risks and uncertainties, rather than as a basis for making changes without individualized medical guidance. [5] [6]

Across two cross-sectional studies in adults with familial Mediterranean fever (FMF), symptom burden and mental burden appeared closely connected. One study focused on attack-related anticipatory anxiety (worry about an oncoming attack) and found it tracked with general anxiety and worse mental quality of life, while another study linked exertional leg pain with higher disease activity and inflammation. Together, the papers suggest that how FMF feels day to day can relate to both mental well-being and measurable inflammation, but the direction of cause and effect remains unclear. [7] [8]

In an exploratory study of 38 adults with FMF, higher attack-related anticipatory anxiety scores were linked to higher generalized anxiety scores and lower mental well-being scores. This study also found that generalized anxiety remained tied to anticipatory anxiety even after considering other factors, suggesting these two experiences often overlap. Direct links between anticipatory anxiety and several combined inflammation measures were weak in this dataset, so blood-based inflammation measures did not clearly explain who had more anticipatory anxiety. [7]

In the same exploratory study, people with a higher annual attack burden had higher levels of standard inflammation markers and lower values in some combined inflammation indices. In plain language, more frequent attacks tended to come with more signs of inflammation in blood tests, even though this did not neatly translate into higher anticipatory anxiety scores. [7]

In a larger retrospective cross-sectional study of 135 FMF patients, exertional leg pain was common and was linked to higher yearly attack frequency and higher disease severity scores. People with exertional leg pain also had higher inflammation markers and more musculoskeletal involvement such as arthritis and enthesitis, while the distribution of MEFV gene variants was similar whether or not leg pain was present. This suggests exertional leg pain may be a marker of higher overall disease activity in some patients, rather than being explained by a specific genetic subgroup. [8]

For patients and caregivers, these studies add context for two common parts of living with FMF: the emotional strain of uncertainty about attacks and the physical strain of pain with activity. The anxiety study mainly helps describe how attack-related worry can connect to broader anxiety and mental quality of life, but it cannot show what causes what, and it used a short questionnaire that still needs validation. The exertional leg pain study suggests this symptom often appears alongside more frequent attacks and higher inflammation, but because it was cross-sectional and clinic-based, it does not prove that leg pain predicts future outcomes or applies to all settings. Overall, the research is most useful now as a better description of symptom and mental health burden in FMF, with open questions about why these patterns occur and how best to measure them. [7] [8]

Across two observational studies, people with familial Mediterranean fever (FMF) showed signs that inflammation can line up with changes in metabolic and oxidative stress-related markers, even outside of acute attacks. One study suggested higher long-term tissue buildup of certain sugar-related compounds in FMF, while another found that two oxidative stress and iron-related markers moved together but were not higher overall during remission. [9] [10]

In a cross-sectional study of 87 FMF patients and 52 healthy controls, tissue advanced glycation end-products (AGEs) measured by a skin light test were higher in FMF. Higher AGE levels also went together with higher inflammatory and metabolic markers and a lower CALLY index (a combined blood-based index that includes inflammation and nutrition-related measures). [9]

In a smaller study of 30 children with FMF in remission and 30 healthy controls, blood levels of malondialdehyde (MDA) and soluble transferrin receptor (sTfR) were similar between groups. Even so, MDA and sTfR were strongly correlated with each other in both FMF and controls, and the FMF group still had higher inflammation markers overall. [10]

For patients and caregivers, these results mainly add background information about how ongoing inflammation in FMF may relate to the body s longer-term metabolic stress signals (like tissue AGE buildup) and to paired oxidative stress and iron-related blood markers. Right now, these studies do not show that any one marker can reliably predict symptoms, flare patterns, or future complications, because they were cross-sectional (one-time measurements) and one focused only on children in remission. More research would be needed to learn whether tracking these markers over time changes understanding of FMF health risks.

Across these studies, cardiovascular (heart and blood vessel) problems were common in people with familial Mediterranean fever (FMF), but the picture was mixed: after accounting for other factors, FMF itself did not clearly act as an independent cause of cardiovascular disease. Instead, traditional risk factors (like diabetes and older age) and markers of more difficult-to-control FMF were the clearest signals linked to higher cardiovascular burden. [11]

In a single-center survey of 522 people with FMF, 38.5% had some form of cardiovascular disease, with high blood pressure being the most common. People with cardiovascular disease more often had diabetes (30.3% vs 10.3%) and more often had colchicine resistance (17.2% vs 7.8%); after adjustment, diabetes and colchicine resistance remained linked to higher cardiovascular morbidity, while FMF itself did not independently raise cardiovascular risk in the adjusted analysis. [11]

That same survey found higher biologic use in those with cardiovascular disease (12.4% vs 5.7%), but biologic therapy was not significant after adjustment, so it is not clear whether this reflects treatment effects or simply that people with more severe inflammation were more likely to receive these medicines. The authors noted this pattern as consistent with the idea that inflammation control could influence cardiovascular risk, but the study design cannot prove cause and effect. [11]

A large nationwide matched-cohort study from Israel (3,324 people with FMF and 13,296 controls) focused on long-term comorbidities rather than cardiovascular disease directly, but it highlighted a different long-run risk relevant to blood vessels and organs: amyloidosis was much more frequent in FMF (1.26% vs 0.015%). Over up to 20 years, FMF was also linked to a higher overall burden of autoimmune and rheumatologic diagnoses compared with matched controls. [12]

For patients and caregivers, these results mainly help with context: heart and blood vessel problems reported in FMF populations may relate more to common risks like diabetes and to harder-to-control FMF (as reflected by colchicine resistance) than to FMF by itself, based on one cross-sectional clinic survey. Separately, the long-term population study reinforces that amyloidosis, while still uncommon, occurred far more often in FMF than in matched controls; how these patterns translate to individual risk remains uncertain because the studies were observational and cannot prove what causes what. [11] [12]

Beyond cardiovascular disease risk, this month included two smaller, exploratory reports that touched on heart-related inflammation and broader health risks in people who have FMF or FMF-related genetics. These papers do not change what is known overall, but they illustrate how FMF genes and FMF itself can intersect with other conditions that affect the heart or other organs. [13] [14]

In a small retrospective study of Turkish children with acute rheumatic fever (60 patients and 60 controls), a MEFV exon 2 variant (E148Q) was more frequent in the acute rheumatic fever group, and the authors discussed a possible connection with heart involvement such as carditis and pericardial effusion. The study did not find differences for MEFV exon 10 mutations, and the authors emphasized that the results are exploratory and need confirmation in larger, multicenter studies. [13]

A case report described one 65-year-old man with FMF who developed duodenal obstruction that was ultimately due to diffuse large B-cell lymphoma, confirmed on biopsy and staged as stage III on imaging. He received R-CHOP chemotherapy and died about five months after diagnosis, highlighting that severe gastrointestinal blockage symptoms in a person with FMF may have causes unrelated to FMF inflammation. [14]

For patients, these studies are mostly background research. The genetics study raises a question about whether one MEFV variant might influence how acute rheumatic fever affects the heart in some children, but the sample was small and the results were not definitive. The single-patient lymphoma report cannot be generalized, but it documents that serious other illnesses can occur alongside FMF and may explain new, severe symptoms. [13] [14]

Across two moderate-sized case-control imaging studies, Familial Mediterranean fever (FMF) was linked to measurable but subtle eye differences compared with healthy people, even when patients were in clinical remission. The changes were selective rather than widespread, and in both studies the M694V gene variant was linked to larger differences. [15] [16]

In a cross-sectional study using optical coherence tomography angiography (a scan that maps tiny blood vessels in the retina), people with FMF had lower blood vessel density in the deep retinal layer in several regions, while the more surface-level retinal vessel layer and other measures (such as the optic nerve and retinal nerve fiber layer) were similar to controls. Older age was the strongest predictor of lower deep-layer vessel density and lower flow in a thin choroidal layer beneath the retina. Within FMF, carrying the M694V variant and having amyloidosis were each linked to lower deep-layer vessel density in the parafoveal and perifoveal regions. [15]

In a prospective case-control study focused on the front of the eye in FMF patients in remission, the cornea showed signs consistent with subclinical endothelial change, including lower endothelial cell density and more variation in cell shape and size, compared with controls. The FMF group also had higher measured eye pressure and a narrower drainage angle on imaging. Among FMF patients, M694V homozygotes had lower corneal endothelial cell density and thicker corneas than M694V heterozygotes. [16]

For patients and caregivers, these studies mainly add background information: they suggest FMF can be linked to small eye changes that may not cause noticeable symptoms, and that certain subgroups (people with the M694V variant, and those with amyloidosis in one study) may show stronger differences on scans. Because both studies were observational and not designed to track changes over time, it is still unclear whether these scan differences predict future eye problems, relate to flare activity, or improve or worsen with changes in overall disease control.

Across published artificial intelligence (AI) research in rheumatology, the overall pattern is rapid growth in the number of papers, but uneven attention across diseases. Familial Mediterranean fever (FMF) appears relatively infrequently compared with much more commonly studied conditions, suggesting that AI tools may be less developed or less tested for FMF so far. [17]

In a bibliometric study that counted and described AI-related rheumatology publications indexed in Scopus up to May 5, 2026, the yearly number of papers rose sharply over time, reaching 282 in 2025. The same analysis reported that osteoarthritis and rheumatoid arthritis dominated disease-focused publications, while FMF accounted for 16 publications in the dataset, indicating underrepresentation. [17]

This paper also noted broader concerns about the field, including the need for stronger ethical and methodological standards and wider international collaboration. These points matter for how trustworthy and broadly usable future AI tools might be, but the study did not evaluate any AI system for FMF in real patients. [17]

For patients and caregivers, this is mainly background research about where scientific attention is going, not a study that changes diagnosis or treatment. The key takeaway is that AI-based approaches in rheumatology are expanding quickly, but FMF has been studied much less than several other conditions, so FMF-specific AI tools may have less evidence behind them at this time. It remains uncertain whether future AI work in FMF will focus on predicting flares, supporting diagnosis, tracking symptoms, or other needs, because this analysis counted publications rather than testing clinical usefulness.